Certara Inc

Certara Inc

CERT

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.3B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Certara IncCertara Inc-18.8--7%4.10.4
$7.75

Target Price by Analysts

6.4% downsideCertara Target Price DetailsTarget Price
$7.83

Current Fair Value

5.4% downside

Overvalued by 5.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.30 Billion
Enterprise Value$1.48 Billion
Dividend Yield$- (-)
Earnings per Share$-0.01
Beta1.41
Outstanding Shares154,356,779

Return

Return on Equity-7.08%ROE
Return on Assets-4.89%
Return on Invested Capital2.25%

Valuation & Multiples

P/E Ratio-18.83P/E Ratio
PEG-0.7PEG
Price to Sales4.14Price to Sales
Price to Book Ratio1.38Price to Book Ratio
Enterprise Value to Revenue3.63
Enterprise Value to EBIT51.62
Enterprise Value to Net Income-22
Total Debt to Enterprise0.25
Debt to Equity0.38Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 5, 2026
EPS Estimate
$0.10
Average shareholder expectation
Revenue Estimate
$98.09 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$0.09
Average shareholder expectation
Revenue Estimate
$92.75 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 2.89%
Total Calls164,800 58.15%
Total Puts- 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %86.32% 2.13%
Total Invested$1.01B 31.34%
Investors Holding244 15.00%

ESG Score

No data

About Certara Inc

300 employees

Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the ...